Difference between revisions of "Team:CU Boulder/project/results"
(9 intermediate revisions by the same user not shown) | |||
Line 46: | Line 46: | ||
-moz-box-shadow: -1px 1px 7px 5px rgba(50, 50, 50, 0.5); | -moz-box-shadow: -1px 1px 7px 5px rgba(50, 50, 50, 0.5); | ||
box-shadow: -1px 1px 7px 5px rgba(50, 50, 50, 0.5); | box-shadow: -1px 1px 7px 5px rgba(50, 50, 50, 0.5); | ||
+ | |||
+ | margin-left: auto; | ||
+ | margin-right: auto; | ||
+ | background-repeat: no-repeat; | ||
} | } | ||
.C4c5_flow { | .C4c5_flow { | ||
Line 53: | Line 57: | ||
background-size: 700px 460px; | background-size: 700px 460px; | ||
background-repeat: no-repeat; | background-repeat: no-repeat; | ||
+ | } | ||
+ | .luxPr1 { | ||
+ | width: 400px; | ||
+ | height: 500px; | ||
+ | background-image: url(https://static.igem.org/mediawiki/2015/b/bf/CU_Boulder_LuxPr1.jpg); | ||
+ | background-size: 400px auto; | ||
+ | } | ||
+ | .luxPr2 { | ||
+ | width: 400px; | ||
+ | height: 500px; | ||
+ | background-image: url(https://static.igem.org/mediawiki/2015/e/e2/CU_Boulder_LuxPr2.jpg); | ||
+ | background-size: 400px auto; | ||
+ | } | ||
+ | .luxPr3 { | ||
+ | width: 700px; | ||
+ | height: 450px; | ||
+ | background-image: url(https://static.igem.org/mediawiki/2015/c/c7/CU_Boulder_LuxPr3.jpg); | ||
+ | background-size: 700px 450px; | ||
} | } | ||
Line 71: | Line 93: | ||
<!----image1----> | <!----image1----> | ||
+ | <div class="frame luxPr1"></div> | ||
+ | <br><br> | ||
<p>Another trial was done in LB. The 100nM sample did not grow.</p> | <p>Another trial was done in LB. The 100nM sample did not grow.</p> | ||
<!---- image 2----> | <!---- image 2----> | ||
+ | <div class="frame luxPr2"></div> | ||
+ | <br><br> | ||
+ | |||
<p>There was a gradient of increasing red color between 0nM through 10nM, which appeared the reddest to | <p>There was a gradient of increasing red color between 0nM through 10nM, which appeared the reddest to | ||
the eye. The samples from trial 5 were suspended in PBS and then run through a flow cytometer to measure | the eye. The samples from trial 5 were suspended in PBS and then run through a flow cytometer to measure | ||
Line 80: | Line 107: | ||
<!----image 3---> | <!----image 3---> | ||
− | <b>Discussion</b> | + | <div class="frame luxPr3"></div> |
+ | <br><br> | ||
+ | |||
+ | |||
+ | <p><b>Discussion</b></p> | ||
<p>All three of the samples with AHL added produced relatively more fluorescence than the negative control. | <p>All three of the samples with AHL added produced relatively more fluorescence than the negative control. | ||
A concentration of 10nm produced the most RFP, so would be the ideal concentration to use according to | A concentration of 10nm produced the most RFP, so would be the ideal concentration to use according to | ||
Line 92: | Line 123: | ||
− | + | <br><br> | |
<!--------------------Switch and GFP--------------------------> | <!--------------------Switch and GFP--------------------------> | ||
<h2>Characterization of Switch with LuxI-GFP</h2> | <h2>Characterization of Switch with LuxI-GFP</h2> |
Latest revision as of 15:15, 18 September 2015
<!DOCTYPE html>